Last updated: October 25, 2026
Chlorpromazine is a mature, off-patent first-generation antipsychotic with limited commercial growth and low strategic value for branded pharmaceutical companies. Its market is sustained by low-cost generic tablets, oral concentrates, and injectable products used in schizophrenia, acute agitation, nausea, intractable hiccups, and selected pediatric or palliative-care settings. The original Thorazine franchise has no meaningful remaining patent or regulatory exclusivity protection in the United States.
The commercial profile is defined by four factors:
- Generic competition has replaced branded pricing power.
- Demand persists because chlorpromazine remains clinically useful in narrow indications.
- Injectable supply is more vulnerable to manufacturing disruptions than tablets.
- Revenue is fragmented among generic manufacturers and is not separately reported by most public companies.
What is chlorpromazine and how is it used?
Chlorpromazine is a phenothiazine dopamine receptor antagonist first introduced in the 1950s. It is marketed primarily as chlorpromazine hydrochloride and is available in oral and injectable forms.
| Attribute |
Chlorpromazine |
| Drug class |
First-generation antipsychotic |
| Chemical class |
Phenothiazine |
| Primary mechanism |
Dopamine D2 receptor antagonism, with anticholinergic, antihistaminic, and alpha-adrenergic effects |
| Original brand |
Thorazine |
| Original innovator |
Smith, Kline & French, later incorporated into GlaxoSmithKline history |
| U.S. approval era |
1950s |
| Main dosage forms |
Tablets, oral solution or concentrate, intramuscular injection |
| Main uses |
Schizophrenia, psychotic disorders, mania, severe behavioral disturbance, nausea and vomiting, intractable hiccups |
| Current commercial status |
Generic, mature, low-price market |
| Biologic status |
Small-molecule drug; biosimilar pathway does not apply |
The drug’s clinical limitations include sedation, orthostatic hypotension, anticholinergic effects, extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, and QT-related cardiac risk. These liabilities have reduced its use in routine long-term psychiatric treatment as newer antipsychotics became available. The FDA label continues to identify serious safety warnings and dosage restrictions across its approved uses. [1]
When did chlorpromazine lose patent exclusivity?
Chlorpromazine lost meaningful U.S. patent protection decades ago. The original composition-of-matter and early formulation rights are historical assets rather than current barriers to generic entry.
| Exclusivity category |
Current position |
| Original composition patent |
Expired |
| Original Thorazine formulation rights |
Expired |
| Small-molecule regulatory exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable to the historic product |
| Pediatric exclusivity |
No current relevance |
| Data exclusivity |
Expired |
| Current U.S. market protection |
None of commercial significance |
The timing of the original patent expirations is less important commercially than the fact that chlorpromazine has been generic for many years. No reasonable generic entrant would expect a patent-based delay comparable to those affecting newer antipsychotics.
What is the Orange Book status of chlorpromazine?
Chlorpromazine products approved in the United States are associated with legacy generic approvals and historical branded approvals. The FDA Orange Book is the controlling source for current approved products, therapeutic equivalence ratings, and any listed patents or exclusivity. [2]
The practical Orange Book position is:
- Chlorpromazine is a conventional abbreviated new drug application market.
- The original branded product does not retain meaningful exclusivity.
- Current generic approvals generally do not depend on a live innovator patent estate.
- Any listed product-specific patent would need to be reviewed by product and dosage form because FDA listings can vary among tablets, oral liquids, and injections.
- A Paragraph IV challenge has limited commercial significance where the relevant product has no enforceable patent blocking generic entry.
For a generic company, the principal regulatory issues are usually bioequivalence, manufacturing compliance, product availability, and market economics rather than patent clearance.
How many patents cover chlorpromazine?
No active, commercially material U.S. patent estate is generally associated with the core chlorpromazine molecule. Historical patents covered the compound and early pharmaceutical formulations, but those rights expired long ago.
| Patent category |
Commercial significance today |
| Core molecule |
None |
| Salt form |
None of practical significance |
| Conventional tablets |
None of practical significance |
| Standard oral concentrate |
None of practical significance |
| Conventional injection |
None of practical significance |
| Novel delivery systems |
Potentially relevant only if independently patented and separately developed |
| Manufacturing process patents |
Unlikely to block ordinary generic production unless tied to a specific protected process |
Patent risk can still arise from a newly developed combination, delivery system, or method of use. Such protection would apply to the new technology, not to ordinary chlorpromazine products. There is no established commercial evidence that a new chlorpromazine formulation has created a significant branded market.
What formulations are protected by chlorpromazine patents?
The commercially important formulations are not protected by surviving foundational patents. Generic chlorpromazine is sold in several dosage forms:
- Tablets in multiple strengths.
- Oral concentrate or solution.
- Intramuscular injection.
- Hospital-use injectable presentations.
Formulation differentiation is limited. Oral products compete mainly on price, availability, bottle size, and wholesaler coverage. Injectable products compete on manufacturing reliability, sterile-facility capacity, contract supply arrangements, and hospital purchasing contracts.
The injectable form has greater operational complexity because sterile manufacturing, particulate control, container closure, stability, and supply continuity affect regulatory and commercial performance. Those barriers are manufacturing barriers rather than durable patent barriers.
What is the FDA regulatory status of chlorpromazine?
Chlorpromazine remains an FDA-approved prescription drug. FDA labeling covers psychiatric and nonpsychiatric indications, including:
- Schizophrenic disorders.
- Acute manic states.
- Severe behavioral problems in selected settings.
- Nausea and vomiting.
- Intractable hiccups.
- Tetanus-related or porphyria-related uses in certain labeling contexts.
- Pediatric indications subject to age, weight, and risk restrictions.
The product is regulated as a conventional small-molecule prescription drug. It is not a biologic and is not subject to the biosimilar approval pathway. Generic versions generally rely on abbreviated new drug applications rather than full clinical efficacy programs. FDA-approved labeling and product availability should be checked through Drugs@FDA and DailyMed because manufacturers and dosage forms change over time. [1,3]
Which companies compete in the chlorpromazine market?
Competition is fragmented. The market has historically included generic manufacturers and specialty suppliers rather than a dominant branded company. Availability varies by dosage form and country.
Relevant competitive groups include:
| Competitor group |
Commercial role |
| Generic oral-drug manufacturers |
Supply tablets and oral liquid products |
| Sterile injectable manufacturers |
Supply hospital injection products |
| Contract manufacturing organizations |
Produce product for marketing authorization holders |
| Regional pharmaceutical companies |
Supply national or tender-based markets |
| Hospital distributors |
Manage institutional purchasing and inventory |
| Compounding pharmacies |
May fill supply gaps where commercially manufactured products are unavailable, subject to local law |
The main competitors to chlorpromazine are not only other chlorpromazine manufacturers. Therapeutic alternatives include haloperidol, fluphenazine, perphenazine, trifluoperazine, risperidone, olanzapine, quetiapine, and other antipsychotics. For nausea, hiccups, and agitation, clinicians may choose drugs from several classes based on safety, setting, and patient characteristics.
How does chlorpromazine compare with newer antipsychotics?
Chlorpromazine has a lower acquisition cost but a less favorable tolerability profile than many newer agents. Its clinical role is therefore concentrated in circumstances where historical familiarity, specific labeled uses, injectable availability, or low price outweigh adverse-effect concerns.
| Factor |
Chlorpromazine |
Newer atypical antipsychotics |
| Patent status |
Long expired |
Often protected historically or recently, depending on product |
| Unit price |
Generally low |
Ranges from generic low-cost products to branded high-cost products |
| Sedation |
High relative burden |
Varies by product |
| Anticholinergic effects |
Significant |
Varies, often lower than chlorpromazine |
| Extrapyramidal symptoms |
Clinically relevant |
Generally lower for many atypicals, though not absent |
| Metabolic effects |
Less dominant than some atypicals |
Can be substantial |
| Injectable use |
Available in conventional injection |
Long-acting injectable alternatives may be available |
| Commercial growth |
Limited |
Product-specific; newer long-acting products have greater growth potential |
Chlorpromazine’s market is defensive rather than expansionary. The drug retains demand where clinicians need an inexpensive conventional antipsychotic or where a particular indication has limited alternatives.
What generic entry risks exist for chlorpromazine?
Generic entry risk is no longer a future event. It has already occurred and reshaped the market.
The principal risks are operational:
- Additional manufacturers can enter if the market supports a viable return.
- Existing suppliers can discontinue low-volume strengths.
- A sterile injectable shortage can produce temporary price increases.
- Hospital buyers can switch among approved suppliers.
- Wholesaler consolidation can intensify price pressure.
- Regulatory manufacturing action can remove a supplier from the market.
Patent litigation risk is low. The more material risk is supply concentration, especially for injectable presentations. A company with a reliable sterile manufacturing network can gain temporary commercial leverage without holding patent protection.
Have there been Paragraph IV challenges involving chlorpromazine?
Paragraph IV litigation is not a central feature of the current chlorpromazine market. The original branded product has been generic for many years, and the absence of a material active patent estate reduces the incentive for new Paragraph IV litigation.
Any Paragraph IV filing would likely concern:
- A newly approved formulation.
- A novel dosage form.
- A combination product.
- A later-developed method of use.
- A specific manufacturer’s listed patent.
Such a filing would not recreate exclusivity around conventional chlorpromazine tablets or injection. The relevant litigation question is product-specific and depends on any patent listed for the particular reference-listed drug or generic application.
What patent litigation and settlement agreements affect chlorpromazine?
There is no major current U.S. patent litigation or settlement framework comparable to those surrounding newer blockbuster drugs. The historical Thorazine franchise predates the modern Hatch-Waxman litigation environment.
No commercially material settlement agreement is generally associated with the ordinary generic chlorpromazine market. Current disputes, where they arise, are more likely to involve:
- Product liability.
- Supply contracts.
- Manufacturing quality.
- Drug shortages.
- Antitrust claims involving distribution.
- Regulatory compliance.
Those matters affect cost and availability but do not create a durable patent moat.
Is there biosimilar risk for chlorpromazine?
Biosimilar risk does not apply. Chlorpromazine is a chemically synthesized small molecule, not a biologic. Its competitive pathway is generic substitution under the abbreviated new drug application framework.
The relevant substitute risk comes from:
- Other generic antipsychotics.
- Long-acting injectable antipsychotics.
- Newer oral atypical antipsychotics.
- Non-antipsychotic treatments for nausea or agitation.
- Institutional treatment protocols that remove older agents from preferred formularies.
What licensing deals involve chlorpromazine?
The commercial history of chlorpromazine includes the original development and commercialization of Thorazine, but the product’s current generic market is not driven by major licensing transactions. Generic rights are typically managed through ordinary marketing authorization, supply, distribution, or contract manufacturing arrangements.
A modern licensing deal would make economic sense only if it involved one of the following:
- A novel delivery system.
- A reformulated product with improved tolerability.
- A combination product.
- A new indication supported by clinical development.
- A regional distribution opportunity in a market with limited supply.
No such platform has produced a widely recognized, high-value global chlorpromazine franchise.
What is the financial trajectory for chlorpromazine?
Chlorpromazine followed the standard financial trajectory of a first-generation medicine:
1950s to 1970s: branded innovation and rapid adoption
Thorazine was a major early antipsychotic product and generated substantial commercial value for its original sponsor. It helped establish the modern pharmacologic treatment of psychosis and became a widely used hospital and psychiatric medicine.
1980s to 1990s: generic erosion and therapeutic substitution
Patent expiry and generic competition compressed prices. Newer antipsychotics began taking share, particularly in chronic outpatient treatment. Brand-level revenue declined as prescribers moved toward products with different efficacy and tolerability profiles.
2000s to present: mature generic and shortage-sensitive demand
Chlorpromazine became a low-price product with stable but narrow demand. Revenue is distributed among manufacturers and is rarely disclosed as a separate line item. Public companies generally report it within broader generic, hospital, or pharmaceutical segments.
| Financial driver |
Effect on chlorpromazine |
| Patent expiry |
Eliminated brand pricing power |
| Generic substitution |
Reduced unit prices |
| Clinical substitution |
Reduced chronic psychiatric volume |
| Hospital demand |
Preserved institutional use |
| Injectable shortages |
Can create temporary pricing and volume volatility |
| Low development cost |
Supports continued generic supply |
| Limited differentiation |
Restricts long-term margin expansion |
| Regulatory withdrawals |
Can shift share rapidly among remaining suppliers |
The economic profile is best characterized as low-margin, mature, and supply-sensitive. Tablets are likely to remain highly price competitive. Injectable products can produce better short-term economics when supply is constrained, but those economics are unstable and may attract additional supply or regulatory scrutiny.
What is the revenue exposure for pharmaceutical companies?
Chlorpromazine revenue exposure is generally immaterial for diversified pharmaceutical companies. The product may be commercially relevant for:
- Small generic manufacturers.
- Hospital-focused suppliers.
- Regional pharmaceutical companies.
- Firms with sterile injectable capacity.
- Distributors supplying psychiatric hospitals or government tenders.
Large pharmaceutical companies typically do not disclose chlorpromazine revenue separately. Reported revenue should therefore be analyzed at the company segment level, not inferred from the drug’s historic brand performance.
A meaningful investment thesis would require evidence of one of three conditions:
- A concentrated market with few approved suppliers.
- A persistent injectable shortage.
- A differentiated formulation or regional supply advantage.
Absent those conditions, chlorpromazine has limited potential to materially affect the valuation of a diversified manufacturer.
How strong is the chlorpromazine patent estate?
The patent estate is weak for conventional products because the core rights expired long ago. Its current competitive protection is based on execution rather than intellectual property.
| Strength category |
Assessment |
| Core composition patent |
None currently material |
| Formulation protection |
Minimal for conventional products |
| Method-of-use protection |
No major current barrier associated with historic uses |
| Regulatory exclusivity |
None of commercial significance |
| Manufacturing know-how |
Moderate operational value for sterile injection |
| Distribution access |
Potentially important in hospital markets |
| Supply reliability |
More important than patents |
| Litigation leverage |
Low |
The absence of patent protection does not mean supply is frictionless. Sterile manufacturing quality, product registration, pharmacovigilance, and procurement access can still limit competition.
What are the geographic market dynamics?
The commercial role of chlorpromazine differs by region.
- United States: mature generic market with limited brand value and periodic supply concerns.
- Europe: generic availability varies by country, national reimbursement policy, and hospital procurement.
- Emerging markets: continued use may be supported by low cost and broad clinical familiarity.
- Low-resource settings: affordability can preserve demand even when newer antipsychotics are preferred in wealthier markets.
- Hospital markets: injectable supply and tender awards can have greater impact than retail advertising.
International patent barriers are generally immaterial because the product is long established. Market access depends more on national registration, local manufacturing, procurement systems, and pharmacovigilance requirements.
What generic launch scenarios are realistic?
Because chlorpromazine is already generic, future launch scenarios involve new suppliers or re-entry rather than first generic entry.
| Scenario |
Likely market effect |
| New tablet supplier enters |
Further price compression and limited share redistribution |
| New injectable supplier enters |
Greater supply resilience and lower shortage premiums |
| Existing supplier exits |
Temporary shortage and higher purchasing leverage for remaining suppliers |
| Novel formulation launches |
Potential niche pricing if clinical benefit is demonstrated |
| Regulatory manufacturing action |
Rapid volume shift to approved competitors |
| Hospital tender win |
Short-term regional share increase without durable patent protection |
A conventional tablet launch has low strategic value unless the entrant has a distribution advantage or unusually low manufacturing cost. An injectable launch can be more attractive because technical barriers and supplier shortages may support better pricing.
Key Takeaways
- Chlorpromazine is a mature generic small-molecule antipsychotic with no meaningful remaining core patent protection.
- Thorazine’s historical brand value has been replaced by fragmented generic supply.
- FDA regulatory exclusivity and ordinary patent-based market protection have expired.
- The Orange Book is relevant for product-level approval and equivalence review, but not for a major current innovator moat.
- Paragraph IV litigation, biosimilar competition, and major settlement agreements are not central to the present market.
- Tablets are commoditized; injectable products have greater supply and manufacturing risk.
- Revenue is generally undisclosed at the individual-product level and is unlikely to be material for diversified pharmaceutical companies.
- The strongest commercial advantages are sterile manufacturing capability, reliable supply, hospital contracting, and regional distribution.
- Future upside would require a differentiated formulation, a supply-constrained injectable market, or a targeted regional strategy.
FAQs About Chlorpromazine Patents, Sales, and Market Competition
Is Thorazine still sold in the United States?
Chlorpromazine remains available through generic products and may be supplied in oral and injectable forms. Brand availability is more limited than during the original Thorazine era.
Can a company obtain exclusivity for a new chlorpromazine product?
A company could potentially obtain patent protection for a genuinely novel formulation, delivery system, combination, or method of use. That protection would not restore exclusivity to conventional chlorpromazine.
Why does chlorpromazine remain in clinical use after newer antipsychotics became available?
Low cost, historical familiarity, labeled indications, and availability in certain hospital settings preserve demand. Use is more selective because of the drug’s adverse-effect profile.
Does chlorpromazine have a long-acting injectable version?
Conventional chlorpromazine injection is available in some markets, but it is distinct from the long-acting injectable formulations developed for several newer antipsychotics. Product availability depends on jurisdiction and manufacturer.
Could chlorpromazine become commercially attractive during a drug shortage?
A shortage can temporarily improve pricing and supplier leverage, particularly for sterile injection. The effect is usually temporary and does not create durable intellectual-property protection.
References
-
U.S. Food and Drug Administration. (n.d.). Chlorpromazine hydrochloride prescribing information. DailyMed and FDA drug labeling resources.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
-
U.S. National Library of Medicine. (n.d.). Chlorpromazine hydrochloride drug information and labeling. DailyMed.
-
World Health Organization. (2023). WHO Model List of Essential Medicines: 23rd list. World Health Organization.
